1. 1) Izumi S, Kamata N, Takeuchi Y, Tanaka A, Hasegawa I, Miyake T, Miyamura S. Academic Committee Academic Subcommittee 1. Investigation and research on appropriate drug therapy for the elderly and patients with chronic kidney disease: investigation on experience of drug-induced side effects and drug-induced nephropathy. J. Jpn. Soc. Hosp. Pharm., 46, 17–21 (2010).
2. 2) Ministry of Health. Labour and Welfare. “NDB. Open Data”. < https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00011.html>. Cited 08 June, 2022.
3. 3) Brooks P, Emercy P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijion-Banos J, Kvien TK, Van Rijiswijk MH, Warner T, Zeidler H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford), 38, 779–788 (1999).
4. 4) Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38, 97–120 (1998).
5. 5) Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat., 68-69, 165–175 (2002).